A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
Price : $35 *
At a glance
- Drugs Modimelanotide (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 03 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 19 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.